NCT05154578: A trial that was reported late by Minervax ApS
This trial has reported, although it was 172 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT05154578 |
|---|---|
| Title | A Multicentre, Multinational, Parallel Group, Observer-blind, Randomised, Placebo-controlled Study on the Group B Streptococcus Vaccine (GBS-NN/NN2), Investigating the Immunogenicity and Safety of Four Vaccination Regimens in Pregnant Woman, Assessing IgG Specific to AlpN Proteins in Cord Blood and Maternal Blood, and the Safety Profile in Mother and Infant up to 6 Months Post-delivery |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Feb. 17, 2022 |
| Completion date | April 26, 2023 |
| Required reporting date | April 25, 2024, midnight |
| Actual reporting date | Oct. 15, 2024 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 172 |